2006
SciTech Defines the IV Formulation for Fenretinide IV Product

• April - SciTech Defines the IV formulation for Fenretinide IV product.

• August- SciTech and CUPSI successfully complete tech transfer process to CUPSI by producing a 50mL batch at CUPSI using an approved batch record.

  Crain’s Detroit Business published SciTech Development among the ten companies that derived their technology from local universities and showed great potential to commercialize their products.

• September - SciTech and SRI complete testing of all candidate elastomers for attachment of cardiac cells and determine the most suitable elastomeric substrate.

• November- CUPSI completes manufacturing of pilot scale batches.

  SciTech relocates to TechTown, a research and technology park encompassing 12 city blocks and acres in Detroit.

• December - SRI and SciTech successfully coat the selected elastomer with patterned laminin in effort to support growth and alignment of the cardiac cells.

2005

• November - Successful transfer of live cardiac cells through mail from Stanford Research Institute (SRI) to our Michigan laboratory. These heart cells have since grown and divided while also reestablishing cardiac rhythm.

• Campbell commenced work on scale-up formulation for IV Retiniod technology.

• January 1 - Breast cancer detection machine modified for simultaneous firing of multiple transducer elements. Successful demonstrations of focusing the ultrasound energy through Time-Reversal Technology. (HIFU)

2004

• November 15 - Struck licensing agreement with Wayne State University in relation to "Parenteral Formulations for Synthetic Retinoids" grant.

• September 24- Awarded $239,947 from NIH for STTR Grant entitled "In Vitro Cardiac Device for Assessing Proarrhythmic Risk".

• September 9 - Research and Product Development Agreement struck between Ferndale Laboratories, Inc. and SciTech in conjunction with "Non-Irratating Topical Products for Difficult Squamous Carcinomas of the Skin." Ferndale is engaged in the development, manufacturing, and commercializing of cosmetic and pharmaceutical products. Ferndale and SciTech will co-develop a product for topical drug treatment of BCC and SCC, and/or other non-melanoma skin cancers.

• September - Phantom breast tests for "Clinical Breast Ultrasound Tomography" grant met resolution, contrast, and locations accuracy targets. 10 patients from WCBCC affirmed the phantom test results as well as ability to differentiate tissue types. A early system has also been established in conjunction with these findings for scoring cancer results.

• May 1 - SciTech and Wayne State University (WSU) entered into an agreement regarding WSU scientists conducting studies for the IV Retinoids grant.

• April 1 - Struck an Intellectual Property Agreement, for the "Parenteral Formulations of Synthetic Retinoids" grant, with Wayne State University.

• April 1 - Awarded $144,683 from NIH for Phase I SBIR Grant entitled "Dynamic Focusing for Non-Invasive Treatments". HIFU technology is applied through the use of a platform breast detection technology. Analogic Corporations begins in joint-development as stated in July 17, 2003 agreement. University of California at Santa Barbara also included in joint-research as designated in "Period of Performance" agreement.

• April - Groupvelocity LLC, Alexander J. Walt Comprehensive Breast Cancer Clinic (WCBCC) at Karmanos Cancer Institute (KCI), and Analogic Corporations begin collaborative work with SciTech on "Clinical Breast Ultrasound Tomography" grant. Groupvelocity, headquartered in Albuquerque, NM, specializes in providing technical and scientific services beyond the scope of conventional consulting. WCBCC, located within the Detroit Medical Center, has become a resource to thousands of women in the metro-Detroit area for breast cancer screening and diagnosis. Analogic is a leading designer and manufacturer of advanced systems and subsystems and are known for advancing Computed Tomography, Digital Radiography, Ultrasound, Magnetic Resonance Imaging, Patient Monitoring, Cardiovascular Information Management, and Embedded Multiprocessing applications.

• April 1 - Awarded $140,800 from NIH for Phase I SBIR Grant entitled "Clinical Breast Ultrasound Tomography". 

2003

• December - Entered in joint-research agreement with Stanford Research Institute.

• December 1- Awarded $1,509,206 from NIH for a Phase II SBIR Grant entitled "Parenteral Formulations for Synthetic Retinoids".

• December - Campbell Pharmaceutical Sciences Institute (CUPSI) and SciTech reach collaborative-research agreement concerning the development of IV Retinoids Therapy. Campbell is a Pharmacy Research Facility designed to enhance the development of innovative academic and research programs.

• October 1 - Licensing Agreement struck with Wayne State University concerning the use of a Vitamin A analog for the development of a topical product to treat Squamous Carcinoma.

• August 10 - An Option Agreement for the acquisition of certain technology/intellectual property needed for development of a topical product to treat Squamous Cell Carcinoma has been struck with Wayne State University.

2001

• September - SciTech was awarded a Phase I  Small Business Innovative Research (SBIR)  grant to develop stereoisomers of arylproprionic acids as cancer chemotherapeutic agents.  The preferred enantiomeric configuration of these compounds is unstable in vivo, and the Phase I grant explores the feasibility of several chemical approaches to stabilizing the more active configurations.  [1R43-CA090088]

• September 17 - Entered in Intellectual Property Disposition concerning the SBIR "Parenteral Formulations for Synthetic Retinoids" Grant

• August - SciTech was awarded a Phase I SBIR grant to develop parenteral formulations of poorly-soluble neutral retinoids that are inactive after oral administration because of very low bioavailability. Intravenous (IV) administration by-passes the limited systemic exposure from oral dosing and potentially achieve levels required to induce apoptosis in human tumor cells via RAR/RXR-independent pathways.

• July 7 - SciTech and University of the Pacific in Stockton, CA, a non-profit university organized and existing under the laws of the State of California, enter into a Research Services Agreement relating to the evaluation, formulation, and administration of certain chemical compounds.